Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7194-7203

  Tai, Wanyi ^a,b   Mo, Ran ^a,b   Lu, Yue ^a,b   Jiang, Tianyue ^a,b   Gu, Zhen ^a,b  

^a USA and North Carolina State University   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bio inspired; Combination therapy; Graft copolymer; Micelle; Nanomedicine; Ring open polymerization

Indexed keywords

BODY FLUIDS; CELL CULTURE; CELLS; DRUG DELIVERY; GRAFT COPOLYMERS; MEDICAL NANOTECHNOLOGY; MICELLES; POLYETHYLENE OXIDES; POLYMERIZATION;

ANTI-CANCER AGENTS; ANTICANCER ACTIVITIES; BIO-INSPIRED; CAMPTOTHECIN (CPT); COMBINATION THERAPY; ENDOCYTOTIC PATHWAY; N-CARBOXYANHYDRIDE; RING OPEN POLYMERIZATION;

POLYETHYLENE GLYCOLS;

CAMPTOTHECIN; CLATHRIN; COPOLYMER; DOXORUBICIN; GRAFT COPOLYMER; MACROGOL; NANOCARRIER; UNCLASSIFIED DRUG; WATER; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; MICELLE; NANOMATERIAL; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; FEMALE; IN VIVO STUDY; LIPID RAFT; LUNG CANCER; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; POLYMERIZATION; PREMATURITY; PRIORITY JOURNAL; PROTEIN FOLDING; TUMOR XENOGRAFT; ANIMAL; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENDOCYTOSIS; HUMAN; MICELLE; NUDE MOUSE; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; ENDOCYTOSIS; FEMALE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICE; MICE, NUDE; MICELLES; NANOSTRUCTURES; POLYETHYLENE GLYCOLS; POLYMERS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902081224     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.004     Document Type: Article

References (70)

1. Persidis A. Cancer multidrug resistance. Nat Biotechnol 1999, 17:94-95.
2. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013, 13:714-726.
3. Scripture C.D., Figg W.D., Sparreboom A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol 2006, 4:165-172.
4. Bovelli D., Plataniotis G., Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Ann Oncol 2010, 21(Suppl.5):v277-v282.
5. LoRusso P.M., Canetta R., Wagner J.A., Balogh E.P., Nass S.J., Boerner S.A., et al. Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. Clin Cancer Res 2012, 18:6101-6109.
6. Joensuu H., Holli K., Heikkinen M., Suonio E., Aro A.R., Hietanen P., et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. JClin Oncol 1998, 16:3720-3730.
7. Podder H., Stepkowski S.M., Napoli K.L., Clark J., Verani R.R., Chou T.C., et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. JAm Soc Nephrol 2001, 12:1059-1071.
8. Bisogno G., Cowie F., Boddy A., Thomas H.D., Dick G., Pinkerton C.R. High-dose cyclosporin with etoposide-toxicity and pharmacokinetic interaction in children with solid tumours. Br J Cancer 1998, 77:2304-2309.
9. Duan X., Xiao J., Yin Q., Zhang Z., Yu H., Mao S., et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 2013, 7:5858-5869.
10. Lehar J., Krueger A.S., Avery W., Heilbut A.M., Johansen L.M., Price E.R., et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009, 27:659-666.
11. Tai W., Qin B., Cheng K. Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF. Mol Pharmacol 2010, 7:543-556.
12. Hu C.M., Aryal S., Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 2010, 1:323-334.
13. Khdair A., Chen D., Patil Y., Ma L., Dou Q.P., Shekhar M.P., et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. JControl Release 2010, 141:137-144.
14. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
15. Shi J., Votruba A.R., Farokhzad O.C., Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010, 10:3223-3230.
16. Chow E.K., Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med 2013, 5:216rv4.
17. Mo R., Jiang T., DiSanto R., Tai W., Gu Z. ATP-triggered anticancer drug delivery. Nat Commun 2014, 5:3364. 10.1038/ncomms4364.
18. Ma L., Kohli M., Smith A. Nanoparticles for combination drug therapy. ACS Nano 2013, 7:9518-9525.
19. Mieszawska A.J., Kim Y., Gianella A., van Rooy I., Priem B., Labarre M.P., et al. Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy. Bioconjug Chem 2013, 24:1429-1434.
20. Wang Y., Ma S., Xie Z., Zhang H. Asynergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles. Colloids Surf B 2013, 116C:41-48.
21. Jiang T., Mo R., Bellotti A., Zhou J., Gu Z. Gel-liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy. Adv Funct Mater 2013, 24:2295-2304.
22. Binaschi M., Zunino F., Capranico G. Mechanism of action of DNA topoisomerase inhibitors. Stem Cells 1995, 13:369-379.
23. Wall M.E., Wani M.C. Camptothecin. Discovery to clinic. Ann N Y Acad Sci 1996, 803:1-12.
24. Wall M.E., Wani M.C. Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995, 55:753-760.
25. Beretta G.L., Perego P., Zunino F. Mechanisms of cellular resistance to camptothecins. Curr Med Chem 2006, 13:3291-3305.
26. Saleem A., Edwards T.K., Rasheed Z., Rubin E.H. Mechanisms of resistance to camptothecins. Ann N Y Acad Sci 2000, 922:46-55.
27. Tan K.B., Mattern M.R., Eng W.K., McCabe F.L., Johnson R.K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. JNatl Cancer Inst 1989, 81:1732-1735.
28. Sugimoto Y., Tsukahara S., Oh-hara T., Liu L.F., Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 1990, 50:7962-7965.
29. Oguro M., Seki Y., Okada K., Andoh T. Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed Pharmacother 1990, 44:209-216.
30. Pavillard V., Kherfellah D., Richard S., Robert J., Montaudon D. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. Br J Cancer 2001, 85:1077-1083.
31. Lu H., Cheng J. N-Trimethylsilyl amines for controlled ring-opening polymerization of amino acid N-carboxyanhydrides and facile end group functionalization of polypeptides. JAm Chem Soc 2008, 130:12562-12563.
32. Lu H., Wang J., Lin Y., Cheng J. One-pot synthesis of brush-like polymers via integrated ring-opening metathesis polymerization and polymerization of amino acid N-carboxyanhydrides. JAm Chem Soc 2009, 131:13582-13583.
33. Thurmond Ii K.B., Huang H., Clark C.G., Kowalewski T., Wooley K.L. Shell cross-linked polymer micelles: stabilized assemblies with great versatility and potential. Colloids Surf B 1999, 16:45-54.
34. Shi Y., van Steenbergen M.J., Teunissen E.A., Novo L., Gradmann S., Baldus M., et al. Pi-pi stacking increases the stability and loading capacity of thermosensitive polymeric micelles for chemotherapeutic drugs. Biomacromolecules 2013, 14:1826-1837.
35. Kataoka K., Matsumoto T., Yokoyama M., Okano T., Sakurai Y., Fukushima S., et al. Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. JControl Release 2000, 64:143-153.
36. Sapra P., Zhao H., Mehlig M., Malaby J., Kraft P., Longley C., et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res 2008, 14:1888-1896.
37. Chen K.J., Tang L., Garcia M.A., Wang H., Lu H., Lin W.Y., et al. The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles. Biomaterials 2012, 33:1162-1169.
38. Boon J.M., Lambert T.N., Smith B.D., Beatty A.M., Ugrinova V., Brown S.N. Structure/activity study of tris(2-aminoethyl)amine-derived translocases for phosphatidylcholine. JOrg Chem 2002, 67:2168-2174.
39. Benito J.M., Gomez-Garcia M., Ortiz Mellet C., Baussanne I., Defaye J., Garcia Fernandez J.M. Optimizing saccharide-directed molecular delivery to biological receptors: design, synthesis, and biological evaluation of glycodendrimer-cyclodextrin conjugates. JAm Chem Soc 2004, 126:10355-10363.
40. Tai W., Chen Z., Barve A., Peng Z., Cheng K. Anovel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer. Pharm Res 2013, 31:706-719.
41. Moretton M.A., Chiappetta D.A., Sosnik A. Cryoprotection-lyophilization and physical stabilization of rifampicin-loaded flower-like polymeric micelles. JR Soc Interface 2012, 9:487-502.
42. Ding M., Song N., He X., Li J., Zhou L., Tan H., et al. Toward the next-generation nanomedicines: design of multifunctional multiblock polyurethanes for effective cancer treatment. ACS Nano 2013, 7:1918-1928.
43. Patist A., Bhagwat S.S., Penfield K.W., Aikens P., Shah D.O. On the measurement of critical micelle concentrations of pure and technical-grade nonionic surfactants. JSurfact Deterg 2000, 3:53-58.
44. Plumb J.A., Milroy R., Kaye S. Effects of the pH dependence of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 1989, 49:4435-4440.
45. Tai W., Shukla R.S., Qin B., Li B., Cheng K. Development of a peptide-drug conjugate for prostate cancer therapy. Mol Pharmacol 2011, 8:901-912.
46. Tai W., Chen Z., Cheng K. Expression profile and functional activity of peptide transporters in prostate cancer cells. Mol Pharmacol 2013, 10:477-487.
47. Xiao L., Xiong X., Sun X., Zhu Y., Yang H., Chen H., et al. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials 2011, 32:5148-5157.
48. Tsai H.-C., Chang W.-H., Lo C.-L., Tsai C.-H., Chang C.-H., Ou T.-W., et al. Graft and diblock copolymer multifunctional micelles for cancer chemotherapy and imaging. Biomaterials 2010, 31:2293-2301.
49. Chen Y.-C., Liao L.-C., Lu P.-L., Lo C.-L., Tsai H.-C., Huang C.-Y., et al. The accumulation of dual pH and temperature responsive micelles in tumors. Biomaterials 2012, 33:4576-4588.
50. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev 2008, 60:899-914.
51. Bhatt R., de Vries P., Tulinsky J., Bellamy G., Baker B., Singer J.W., et al. Synthesis and invivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. JMed Chem 2003, 46:190-193.
52. Singer J.W., Bhatt R., Tulinsky J., Buhler K.R., Heasley E., Klein P., et al. Water-soluble poly-(L-glutamic acid)-gly-camptothecin conjugates enhance camptothecin stability and efficacy invivo. JControl Release 2001, 74:243-247.
53. He C., Hu Y., Yin L., Tang C., Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31:3657-3666.
54. Frohlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine 2012, 7:5577-5591.
55. Krasnici S., Werner A., Eichhorn M.E., Schmitt-Sody M., Pahernik S.A., Sauer B., et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003, 105:561-567.
56. Deming T.J., Curtin S.A. Chain Initiation efficiency in cobalt- and nickel-mediated polypeptide synthesis. JAm Chem Soc 2000, 122:5710-5717.
57. Basu S., De S., Bhowmik B.B. Photophysical studies of merocyanine 540 dye in aqueous micellar dispersions of different surfactants and in different solvents. Spectrochim Acta A Mol Biomol Spectrosc 2007, 66:1255-1260.
58. Kaschny P., Goni F.M. The components of merocyanine-540 absorption spectra in aqueous, micellar and bilayer environments. Eur J Biochem 1992, 207:1085-1091.
59. Sung J., Shin K.J., Lee S. Effects of static quenching and light pulse intensity on the time-dependent fluorescence quenching kinetics. Chem Phys 1994, 179:23-37.
60. Berlier J.E., Rothe A., Buller G., Bradford J., Gray D.R., Filanoski B.J., et al. Quantitative comparison of long-wavelength alexa fluor dyes to cy dyes: fluorescence of the dyes and their bioconjugates. JHistochem Cytochem 2003, 51:1699-1712.
61. Shuai X., Ai H., Nasongkla N., Kim S., Gao J. Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. JControl Release 2004, 98:415-426.
62. Heuser J.E., Anderson R.G. Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation. JCell Biol 1989, 108:389-400.
63. Wang L.H., Rothberg K.G., Anderson R.G. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. JCell Biol 1993, 123:1107-1117.
64. Singh R.D., Puri V., Valiyaveettil J.T., Marks D.L., Bittman R., Pagano R.E. Selective caveolin-1-dependent endocytosis of glycosphingolipids. Mol Biol Cell 2003, 14:3254-3265.
65. Nishimura S., Takahashi S., Kamikatahira H., Kuroki Y., Jaalouk D.E., O'Brien S., et al. Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells. JBiol Chem 2008, 283:11752-11762.
66. Araki N., Johnson M.T., Swanson J.A. Arole for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages. JCell Biol 1996, 135:1249-1260.
67. Kabouridis P.S., Janzen J., Magee A.L., Ley S.C. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur J Immunol 2000, 30:954-963.
68. Chipman S.D., Oldham F.B., Pezzoni G., Singer J.W. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine 2006, 1:375-383.
69. Schluep T., Hwang J., Cheng J., Heidel J.D., Bartlett D.W., Hollister B., et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 2006, 12:1606-1614.
70. Gabizon A.A. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 2001, 7:223-225.